title: Effect of lipo-prostaglandin E1 on cystatin C, β2-microglobulin, and estimated glomerular filtration rate in patients with decompensated heart failure and renal dysfunction: a single-center, nonrandomized controlled study.
abstract: A nonrandomized controlled study was conducted to evaluate the effect of lipo-prostaglandin E1 (lipo-PGE1) on cystatin C (CysC), β2-microglobulin (B2MG), and estimated glomerular filtration rate (eGFR) in patients with decompensated heart failure (DHF) and renal dysfunction. A total of 286 enrolled patients with DHF and renal dysfunction were nonrandomly assigned a 7-day standard treatment without (n = 146) or with (n = 140) lipo-PGE1 intervention. According to the baseline eGFR, patients were further classified into mild, moderate, and severe renal dysfunction subgroups. By the end of study period, there was no evidence of an immense improvement in B2MG, CysC, and eGFR in response to standard treatment (all P > 0.05). On the contrary, a noticeable decrease of B2MG and CysC was observed in patients receiving lipo-PGE1 intervention, as well as an increase in eGFR (all P < 0.05). Moreover, lipo-PGE1 intervention led to greater changes in renal function variables from baseline than with standard management (all P < 0.05). Most important, the favorable renal protective effects of lipo-PGE1 were maintained in three subgroups. Lipo-PGE1 intervention brought a substantial renoprotective benefit to hospitalized DHF patients as compared with standard therapy, suggesting it might offer a promising therapeutic option for the management of renal dysfunction associated with DHF.
authors.affiliation: Emergency Department, Shandong Provincial Hospital Affiliated to Shandong University, 324, Jing Wu Road, Jinan, 250021, Shandong, China.
authors.forename: Zhi-Qiang
authors.initials: ZQ
authors.lastname: Hou
authors.forename: Zhao-Xia
authors.initials: ZX
authors.lastname: Sun
authors.forename: Chong-Yi
authors.initials: CY
authors.lastname: Su
authors.forename: Hui
authors.initials: H
authors.lastname: Tan
authors.forename: Xia
authors.initials: X
authors.lastname: Zhong
authors.forename: Bo
authors.initials: B
authors.lastname: Hu
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: De-Ya
authors.initials: DY
authors.lastname: Shang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002681:China; D055316:Cystatin C / Q000097:blood*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006760:Hospitalization; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007674:Kidney Diseases / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D013997:Time Factors; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D015415:Biomarkers; C525030:CST3 protein, human; D002317:Cardiovascular Agents; D055316:Cystatin C; D001613:beta 2-Microglobulin; D000527:Alprostadil